AKEBIA THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
AKEBIA THERAPEUTICS, INC. (AKBA) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 12-month period ending 2022-12-31, per its 10-K/A filed 2023-08-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2023-08-28
- AKEBIA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2021-12-31 was $0.00.
- AKEBIA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2020-12-31 was $0.00.
- AKEBIA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2020-09-30 was $49.98M.
- AKEBIA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $0.00.
- AKEBIA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- AKEBIA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2020 was $99.93M.
- AKEBIA THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K/A · filed 2023-08-28 | |||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $0.00 derived: sum of 2 quarters · filed 2023-08-28 | $0.00 10-K/A · filed 2023-08-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 | |||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $49.98M derived: sum of 2 quarters · filed 2023-08-28 | $99.93M 10-K/A · filed 2023-08-28 | |
| 2020-09-30 | $49.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $99.93M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $49.95M 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | $51.78M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $102.75M derived: sum of 2 quarters · filed 2021-02-25 | $175.62M derived: sum of 3 quarters · filed 2021-02-25 | $224.22M 10-K · filed 2021-02-25 |
| 2018-09-30 | $50.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $123.84M derived: sum of 2 quarters · filed 2019-11-12 | $172.44M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $72.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $121.47M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $48.60M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $330.64M 10-K · filed 2020-03-12 | |||
| 2016-12-31 | $147.01M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |